QuantRx Biomedical Corporation (QTXB)
USD 0.0
(-0.0%)
USD 0.0
(-0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -43.38 Thousand USD | 28.44% |
| 2020 | -60.62 Thousand USD | 69.95% |
| 2019 | -201.73 Thousand USD | 14.47% |
| 2018 | -235.87 Thousand USD | -42.81% |
| 2017 | -165.17 Thousand USD | -18.97% |
| 2016 | -138.83 Thousand USD | 61.29% |
| 2015 | -358.7 Thousand USD | 22.44% |
| 2014 | -462.48 Thousand USD | -22.69% |
| 2013 | -376.96 Thousand USD | 23.74% |
| 2012 | -494.28 Thousand USD | 37.96% |
| 2011 | -796.76 Thousand USD | 60.26% |
| 2010 | -2 Million USD | 16.61% |
| 2009 | -2.4 Million USD | 57.82% |
| 2008 | -5.69 Million USD | 4.82% |
| 2007 | -5.98 Million USD | -98.85% |
| 2006 | -3.01 Million USD | -181.96% |
| 2005 | -1.06 Million USD | -1071.27% |
| 2004 | -91.18 Thousand USD | -82.12% |
| 2003 | -50.07 Thousand USD | 58.02% |
| 2002 | -119.27 Thousand USD | 86.45% |
| 2001 | -880 Thousand USD | 53.44% |
| 2000 | -1.89 Million USD | 24.4% |
| 1999 | -2.5 Million USD | 45.77% |
| 1998 | -4.61 Million USD | -14.68% |
| 1997 | -4.02 Million USD | 7.37% |
| 1996 | -4.34 Million USD | -5.6% |
| 1995 | -4.11 Million USD | -291.43% |
| 1994 | -1.05 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q1 | -3606.00 USD | 45.06% |
| 2022 Q2 | -26.9 Thousand USD | -645.98% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q3 | -7250.00 USD | 73.05% |
| 2021 Q3 | -8542.00 USD | 63.23% |
| 2021 Q2 | -23.23 Thousand USD | -360.29% |
| 2021 FY | -43.38 Thousand USD | 28.44% |
| 2021 Q1 | -5047.00 USD | 44.49% |
| 2021 Q4 | -6563.00 USD | 23.17% |
| 2020 Q3 | -10.69 Thousand USD | 57.97% |
| 2020 Q4 | -9092.00 USD | 14.96% |
| 2020 Q2 | -25.44 Thousand USD | -65.19% |
| 2020 Q1 | -15.4 Thousand USD | 57.25% |
| 2020 FY | -60.62 Thousand USD | 69.95% |
| 2019 FY | -201.73 Thousand USD | 14.47% |
| 2019 Q1 | -59 Thousand USD | 26.56% |
| 2019 Q2 | -61.83 Thousand USD | -4.8% |
| 2019 Q3 | -44.87 Thousand USD | 27.42% |
| 2019 Q4 | -36.02 Thousand USD | 19.74% |
| 2018 Q3 | -25.58 Thousand USD | 69.41% |
| 2018 Q4 | -80.34 Thousand USD | -214.03% |
| 2018 Q2 | -83.64 Thousand USD | -79.48% |
| 2018 Q1 | -46.6 Thousand USD | 23.46% |
| 2018 FY | -235.87 Thousand USD | -42.81% |
| 2017 Q3 | -32.74 Thousand USD | 6.5% |
| 2017 FY | -165.17 Thousand USD | -18.97% |
| 2017 Q1 | -36.5 Thousand USD | -14.77% |
| 2017 Q2 | -35.02 Thousand USD | 4.06% |
| 2017 Q4 | -60.89 Thousand USD | -85.94% |
| 2016 FY | -138.83 Thousand USD | 61.29% |
| 2016 Q1 | -26.64 Thousand USD | 62.73% |
| 2016 Q4 | -31.81 Thousand USD | -18.22% |
| 2016 Q3 | -26.9 Thousand USD | 49.68% |
| 2016 Q2 | -53.47 Thousand USD | -100.7% |
| 2015 Q2 | -38.76 Thousand USD | 77.62% |
| 2015 FY | -358.7 Thousand USD | 22.44% |
| 2015 Q4 | -71.48 Thousand USD | 4.99% |
| 2015 Q1 | -173.21 Thousand USD | -33.09% |
| 2015 Q3 | -75.24 Thousand USD | -94.13% |
| 2014 Q3 | -83.73 Thousand USD | 46.6% |
| 2014 Q4 | -130.14 Thousand USD | -55.42% |
| 2014 Q1 | -91.79 Thousand USD | 52.4% |
| 2014 Q2 | -156.8 Thousand USD | -70.83% |
| 2014 FY | -462.48 Thousand USD | -22.69% |
| 2013 Q2 | -90.13 Thousand USD | -99.27% |
| 2013 Q3 | -48.75 Thousand USD | 45.91% |
| 2013 Q4 | -192.82 Thousand USD | -295.47% |
| 2013 Q1 | -45.23 Thousand USD | -259.66% |
| 2013 FY | -376.96 Thousand USD | 23.74% |
| 2012 Q4 | -12.57 Thousand USD | 92.01% |
| 2012 Q2 | -183.87 Thousand USD | -30.96% |
| 2012 Q3 | -157.42 Thousand USD | 14.38% |
| 2012 Q1 | -140.4 Thousand USD | 45.31% |
| 2012 FY | -494.28 Thousand USD | 37.96% |
| 2011 Q4 | -256.73 Thousand USD | -65.29% |
| 2011 FY | -796.76 Thousand USD | 60.26% |
| 2011 Q3 | -155.31 Thousand USD | 41.66% |
| 2011 Q2 | -266.22 Thousand USD | -124.67% |
| 2011 Q1 | -118.49 Thousand USD | 69.09% |
| 2010 FY | -2 Million USD | 16.61% |
| 2010 Q3 | -734.97 Thousand USD | -100.27% |
| 2010 Q1 | -519.42 Thousand USD | -23.73% |
| 2010 Q2 | -366.99 Thousand USD | 29.35% |
| 2010 Q4 | -383.37 Thousand USD | 47.84% |
| 2009 Q3 | -1.03 Million USD | -200.02% |
| 2009 Q2 | -344.21 Thousand USD | 64.26% |
| 2009 Q4 | -419.79 Thousand USD | 59.35% |
| 2009 Q1 | -963.2 Thousand USD | 1.38% |
| 2009 FY | -2.4 Million USD | 57.82% |
| 2008 Q2 | -1.75 Million USD | -15.8% |
| 2008 Q1 | -1.51 Million USD | -22.44% |
| 2008 FY | -5.69 Million USD | 4.82% |
| 2008 Q4 | -976.69 Thousand USD | 32.34% |
| 2008 Q3 | -1.44 Million USD | 17.96% |
| 2007 Q3 | -1.38 Million USD | 38.83% |
| 2007 FY | -5.98 Million USD | -98.85% |
| 2007 Q2 | -2.27 Million USD | -108.84% |
| 2007 Q4 | -1.24 Million USD | 10.65% |
| 2007 Q1 | -1.08 Million USD | -18.2% |
| 2006 Q4 | -919.9 Thousand USD | -32.19% |
| 2006 Q2 | -803.15 Thousand USD | -35.58% |
| 2006 Q1 | -592.36 Thousand USD | -108.97% |
| 2006 FY | -3.01 Million USD | -181.96% |
| 2006 Q3 | -695.9 Thousand USD | 13.35% |
| 2005 Q3 | -522.12 Thousand USD | -141.37% |
| 2005 Q1 | -46.1 Thousand USD | 31.9% |
| 2005 Q4 | -283.46 Thousand USD | 45.71% |
| 2005 FY | -1.06 Million USD | -1071.27% |
| 2005 Q2 | -216.31 Thousand USD | -369.17% |
| 2004 Q1 | -11.47 Thousand USD | 0.0% |
| 2004 Q2 | -3024.00 USD | 73.65% |
| 2004 Q3 | -6566.00 USD | -117.13% |
| 2004 Q4 | -67.7 Thousand USD | -931.18% |
| 2004 FY | -91.18 Thousand USD | -82.12% |
| 2003 FY | -50.07 Thousand USD | 58.02% |
| 2002 FY | -119.27 Thousand USD | 86.45% |
| 2002 Q1 | -40 Thousand USD | 63.64% |
| 2001 Q4 | -110 Thousand USD | 38.89% |
| 2001 FY | -880 Thousand USD | 53.44% |
| 2001 Q3 | -180 Thousand USD | 30.77% |
| 2001 Q2 | -260 Thousand USD | 21.21% |
| 2001 Q1 | -330 Thousand USD | 26.67% |
| 2000 Q4 | -450 Thousand USD | 6.25% |
| 2000 FY | -1.89 Million USD | 24.4% |
| 2000 Q1 | -470 Thousand USD | 14.55% |
| 2000 Q2 | -480 Thousand USD | -2.13% |
| 2000 Q3 | -480 Thousand USD | 0.0% |
| 1999 Q4 | -550 Thousand USD | 11.29% |
| 1999 Q3 | -620 Thousand USD | 3.13% |
| 1999 Q1 | -690 Thousand USD | 47.73% |
| 1999 FY | -2.5 Million USD | 45.77% |
| 1999 Q2 | -640 Thousand USD | 7.25% |
| 1998 Q2 | -890 Thousand USD | 26.45% |
| 1998 Q1 | -1.21 Million USD | 27.11% |
| 1998 Q3 | -1.19 Million USD | -33.71% |
| 1998 Q4 | -1.32 Million USD | -10.92% |
| 1998 FY | -4.61 Million USD | -14.68% |
| 1997 Q4 | -1.66 Million USD | -118.42% |
| 1997 FY | -4.02 Million USD | 7.37% |
| 1997 Q3 | -760 Thousand USD | 21.65% |
| 1997 Q2 | -970 Thousand USD | -53.97% |
| 1997 Q1 | -630 Thousand USD | 59.09% |
| 1996 Q2 | -1.07 Million USD | -5.94% |
| 1996 FY | -4.34 Million USD | -5.6% |
| 1996 Q4 | -1.54 Million USD | -113.89% |
| 1996 Q3 | -720 Thousand USD | 32.71% |
| 1996 Q1 | -1.01 Million USD | 0.98% |
| 1995 Q3 | -1 Million USD | 14.53% |
| 1995 Q4 | -1.02 Million USD | -2.0% |
| 1995 Q2 | -1.17 Million USD | -24.47% |
| 1995 Q1 | -940 Thousand USD | -95.83% |
| 1995 FY | -4.11 Million USD | -291.43% |
| 1994 Q1 | -230 Thousand USD | 0.0% |
| 1994 Q3 | -160 Thousand USD | 5.88% |
| 1994 Q4 | -480 Thousand USD | -200.0% |
| 1994 Q2 | -170 Thousand USD | 26.09% |
| 1994 FY | -1.05 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | 100.0% |
| Ansell Limited | 129.3 Million USD | 100.0% |
| Ansell Limited | 129.3 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | 31.13 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -1.59 Million USD | 100.0% |
| Psykey, Inc. | -797.5 Thousand USD | 100.0% |
| ConvaTec Group Plc | 262.7 Million USD | 100.0% |
| ConvaTec Group Plc | 262.7 Million USD | 100.0% |
| Encision Inc. | -640.78 Thousand USD | 100.0% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 100.0% |
| Innovative MedTech Inc. | -4.27 Million USD | 100.0% |
| LifePoint, Inc. | -7.49 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | 100.0% |
| Remedent, Inc. | -122.89 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | -241.15 Million USD | 100.0% |
| Sector 10, Inc. | -39.84 Thousand USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | 100.0% |
| SheerVision, Inc. | 155.72 Thousand USD | 100.0% |
| United Health Products, Inc. | -2.42 Million USD | 100.0% |
| Vasamed, Inc. | 4.74 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 100.0% |
| Yubo International Biotech Limited | -1.2 Million USD | 100.0% |